Corticosteroids reduce pathologic interferon responses by downregulating STAT1 in patients with high-risk COVID-19
暂无分享,去创建一个
E. Shin | S. Oh | K. Peck | Sung-Han Kim | Seunghee Hong | Ji Hun Yang | Jeong Seok Lee | J. Ko | Seongkyun Choi | H. Jeong | Yeon-Sook Kim | Seok Chung
[1] P. Sivaprakash,et al. Mucormycosis: An opportunistic pathogen during COVID-19 , 2021, Environmental Research.
[2] C. D. Dela Cruz,et al. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection , 2021, Science Immunology.
[3] E. Shin,et al. Type I and III interferon responses in SARS-CoV-2 infection , 2021, Experimental & Molecular Medicine.
[4] D. Brodie,et al. Post-acute COVID-19 syndrome , 2021, Nature Medicine.
[5] A. Iwasaki,et al. The first 12 months of COVID-19: a timeline of immunological insights , 2021, Nature reviews. Immunology.
[6] J. Schultze,et al. COVID-19 and the human innate immune system , 2021, Cell.
[7] Pingping Wang,et al. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas , 2021, Cell.
[8] E. Shin,et al. SARS-CoV-2-Specific T Cell Responses in Patients with COVID-19 and Unexposed Individuals , 2021, Immune network.
[9] Steven M. Holland,et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.
[10] Jacques Fellay,et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.
[11] Keith Sigel,et al. An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.
[12] I. Amit,et al. The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing , 2020, medRxiv.
[13] E. Shin,et al. The type I interferon response in COVID-19: implications for treatment , 2020, Nature Reviews Immunology.
[14] Alexander Sczyrba,et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment , 2020, Cell.
[15] A. Iwasaki,et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling , 2020, The Journal of experimental medicine.
[16] Eric Song,et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19 , 2020, Nature.
[17] Aaron M. Rosenfeld,et al. Comprehensive mapping of immune perturbations associated with severe COVID-19 , 2020, Science Immunology.
[18] S. Perlman,et al. Lessons for COVID-19 Immunity from Other Coronavirus Infections , 2020, Immunity.
[19] Inkyung Jung,et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19 , 2020, Science Immunology.
[20] V. Pascual,et al. Mapping Systemic Lupus Erythematosus heterogeneity at the single-cell level , 2020, Nature Immunology.
[21] X. Tang,et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.
[22] Aaron J. Wilk,et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19 , 2020, Nature Medicine.
[23] Eric Song,et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling , 2020, bioRxiv.
[24] I. Amit,et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.
[25] M. Merad,et al. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages , 2020, Nature Reviews Immunology.
[26] M. Netea,et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure , 2020, Cell Host & Microbe.
[27] E. Holmes,et al. A new coronavirus associated with human respiratory disease in China , 2020, Nature.
[28] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[29] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[30] I. Bruce,et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. , 2019, The New England journal of medicine.
[31] S. Anderson,et al. Differential Activation of the Transcription Factor IRF1 Underlies the Distinct Immune Responses Elicited by Type I and III Interferons. , 2019, Immunity.
[32] E. Lee,et al. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids , 2017, Annals of the rheumatic diseases.
[33] I. Fraser,et al. Anti‐Inflammatory Chromatinscape Suggests Alternative Mechanisms of Glucocorticoid Receptor Action , 2017, Immunity.
[34] Eugenia G. Giannopoulou,et al. Type I IFNs and TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation , 2017, Nature Immunology.
[35] G. Stark,et al. Response to interferons and antibacterial innate immunity in the absence of tyrosine‐phosphorylated STAT1 , 2016, EMBO reports.
[36] David K. Meyerholz,et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice , 2016, Cell Host & Microbe.
[37] J. Mesirov,et al. The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .
[38] D. Park,et al. Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness , 2015, Proceedings of the National Academy of Sciences.
[39] A. Sher,et al. Type I interferons in infectious disease , 2015, Nature Reviews Immunology.
[40] D. Granger,et al. Blood cells and endothelial barrier function , 2015, Tissue barriers.
[41] C. Rice,et al. IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage , 2013, The EMBO journal.
[42] Gary B. Smith,et al. The ability of the National Early Warning Score (NEWS) to discriminate patients at risk of early cardiac arrest, unanticipated intensive care unit admission, and death. , 2013, Resuscitation.
[43] M. David,et al. Immunomodulatory functions of type I interferons , 2012, Nature Reviews Immunology.
[44] B. Lask,et al. Implications for Treatment , 2011 .
[45] W. Hörl,et al. Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells. , 2011, Blood.
[46] Mahboob Rahman,et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. , 2006, Arthritis and rheumatism.
[47] L. Platanias. Mechanisms of type-I- and type-II-interferon-mediated signalling , 2005, Nature Reviews Immunology.
[48] Sergio Romagnani,et al. CXC chemokines: the regulatory link between inflammation and angiogenesis. , 2004, Trends in immunology.
[49] J. Kirwan,et al. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. , 1995, The New England journal of medicine.
[50] M. Schauer,et al. Binding of hormone accelerates the kinetics of glucocorticoid and progesterone receptor binding to DNA. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[51] P. Hench,et al. Adrenocortical Hormone in Arthritis * , 1949, Annals of the rheumatic diseases.
[52] W. Lim,et al. Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .
[53] E. Cesse,et al. Lessons from COVID-19 , 2021, Revista Brasileira de Saúde Materno Infantil.
[54] J. Mesirov,et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.
[55] M. Ryser-Degiorgis. Other coronavirus infections , 2012 .